Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 54, Issue 4, Pages 683-687
Publisher
Informa UK Limited
Online
2012-09-12
DOI
10.3109/10428194.2012.728597
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
- (2012) K Giannopoulos et al. BRITISH JOURNAL OF CANCER
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma
- (2012) Yibin Yang et al. CANCER CELL
- The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
- (2012) Walter M. T. Braga et al. Clinical & Developmental Immunology
- Functional modulation of AMP-activated protein kinase by cereblon
- (2011) Kwang Min Lee et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors
- (2011) P. Neri et al. BLOOD
- Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
- (2011) S. Madan et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
- (2011) Antonia Lopez-Girona et al. BRITISH JOURNAL OF HAEMATOLOGY
- Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients
- (2011) T. Guglielmelli et al. EUROPEAN JOURNAL OF CANCER
- Pomalidomide therapy for multiple myeloma and myelofibrosis: an update
- (2011) Martha Q. Lacy et al. LEUKEMIA & LYMPHOMA
- Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
- (2010) Chad C. Bjorklund et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
- (2009) L. Escoubet-Lozach et al. CANCER RESEARCH
- Mechanism of action of lenalidomide in hematological malignancies
- (2009) Venumadhav Kotla et al. Journal of Hematology & Oncology
- Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
- (2009) H Quach et al. LEUKEMIA
- Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
- (2009) C. Therapontos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- (2008) M. Wang et al. BLOOD
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial
- (2008) A. Palumbo et al. BLOOD
- Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation
- (2008) Dan Zhu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
- (2008) Christine Galustian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
- (2008) I Breitkreutz et al. LEUKEMIA
- IRF4 addiction in multiple myeloma
- (2008) Arthur L. Shaffer et al. NATURE
- Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation
- (2008) Joseph J. Higgins et al. NEUROGENETICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now